Find out everything you need to know about the latest pricing, reimbursement and market access strategies that will drive your business development.
Following a quarter that featured reports stating that Novartis had dramatically redistributed its cell and gene therapy unit 1 and saw the public focus turn once again to drug price hikes, Pharma IQ brings you the pharma, biotech and life sciences news highlights for Q3 of 2016. Full Article »
Japanese pharmaceutical giant Eisai has launched a new epilepsy drug in Europe following approval by the European Commission.
Discovered and developed in the United Kingdom, Fycompa® (perampanel) is an important new addition to the treatment of epilepsy in Europe as it has efficacy in difficult-to-treat patients with uncontrolled partial o Full Video »
Diabetes is a global threat. Researchers estimate that 26.6 million people in the Middle East and North Africa currently have diabetes. Six countries in the region are among the top 10 globally with the highest prevalence of diabetes. In this interview Professor Peter Schwarz, Head of Department of Prevention and Care of Diabetes University Full Podcast »
Extensive investigator networks, cultivated over the course of some of the world’s largest clinical trials into the risk factors for dementia, present an exciting opportunity for the future of dementia trials. Diabetes, hypertension, stroke, vascular disease, smoking, poor diet, physical inactivity and even depression have been linked to an increase in the likelihood of an individual presenting with dementia at some point in their lives Full Column »
Ahead of this year’s Early Access Programmes Europe conference, Pharma IQ expands its regulatory handbook to develop the industry’s awareness of the various compliance requirements that surround the implementation of these programmes Full Whitepaper »